Paper Details

  1. Home
  2. Paper Details

A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Author: JaffriSayyed Farhan A, MathewNinan T

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

OnabotulinumtoxinA and topiramate showed similar efficacy in reducing headache days and improving disability in patients with chronic migraine (CM). OnabotulinumtoxinA had fewer adverse events and discontinuations, suggesting it may be a preferred option.
Paper Details　
Original Abstract of the Article :
BACKGROUND: There is a need for effective prophylactic therapy for chronic migraine (CM) that has minimal side effects. OBJECTIVE: To compare the efficacy and safety of onabotulinumtoxinA (BOTOX), Allergan, Inc., Irvine, CA) and topiramate (TOPAMAX), Ortho-McNeil, Titusville, NJ) prophylactic treat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1526-4610.2009.01566.x

データ提供：米国国立医学図書館（NLM）

A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX) and Topiramate (TOPAMAX) for the Prophylactic Treatment of Chronic Migraine

The realm of [neurology] is constantly seeking new solutions for chronic migraine, a debilitating condition that significantly impacts quality of life. This study utilizes a [double-blind, placebo-controlled trial] to compare the efficacy and safety of two popular prophylactic treatments for chronic migraine: onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX). The researchers found that both treatments demonstrated similar efficacy in reducing migraine frequency and improving quality of life. However, patients receiving onabotulinumtoxinA experienced fewer adverse events and discontinuations compared to those receiving topiramate.

OnabotulinumtoxinA Offers a More Favorable Treatment Profile

This research suggests that onabotulinumtoxinA may be a preferable option for the prophylactic treatment of chronic migraine due to its favorable safety profile. The study found that patients receiving onabotulinumtoxinA experienced fewer adverse events and were less likely to discontinue treatment compared to those receiving topiramate. This is important for patients with chronic migraine, who often experience significant limitations in their daily lives and may be hesitant to try new treatments due to concerns about side effects.

Understanding the Benefits and Risks of Migraine Treatments

The research highlights the importance of individualizing treatment approaches for chronic migraine. While both onabotulinumtoxinA and topiramate showed similar efficacy in reducing migraine frequency and improving quality of life, the lower incidence of adverse events with onabotulinumtoxinA may make it a more attractive option for some patients.

Dr.Camel's Conclusion

Migraines can be a real camel breaker, making it difficult to navigate the sands of life. This research offers a more thorough understanding of two commonly used treatments for chronic migraine. The findings suggest that onabotulinumtoxinA might be a more manageable option for many individuals due to its favorable side effect profile. Ultimately, the best treatment option for chronic migraine depends on the individual's specific needs and preferences.
Date :
  1. Date Completed 2011-08-04
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

19912346

DOI: Digital Object Identifier

10.1111/j.1526-4610.2009.01566.x

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.